NCT00473590View on ClinicalTrials.gov

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

Bevacizumab

15 mg/kg administered by intravenous infusion

DRUG

Bortezomib

1.3 mg/m\^2 administered by intravenous bolus injection

DRUG

placebo

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY